Gross Margin Expansion of 79 Basis Points
Adjusted EPS Growth of Nearly Four Times with GAAP EPS Loss of $ and Adjusted EPS of $0.19
Investments Outlined at 2023 Investor Day for Long-Term Growth.
Outlines new five-year strategic plan intended to unlock expanded profitability and growth profiles of the business, targeting 20% compounded earnings growth between 2024 to 2028
Investments and.
Top Line Expansion Led by Healthy Demand in Patient Direct and Medical Distribution
Operating Cash Flow Generation Supported $188 million in Total Debt Reduction
.
Strength of Patient Direct Drove Gross Margin Expansion
Operating Model Realignment Program Remains on Track
Raised Midpoint of 2023 Guidance Based on Strong Patient Direct Performance and Profit. | May 5, 2023